HUE030976T2 - Tramadol és NSAID-ok kokristályai - Google Patents
Tramadol és NSAID-ok kokristályai Download PDFInfo
- Publication number
- HUE030976T2 HUE030976T2 HUE09736862A HUE09736862A HUE030976T2 HU E030976 T2 HUE030976 T2 HU E030976T2 HU E09736862 A HUE09736862 A HU E09736862A HU E09736862 A HUE09736862 A HU E09736862A HU E030976 T2 HUE030976 T2 HU E030976T2
- Authority
- HU
- Hungary
- Prior art keywords
- tramadol
- crystal
- naproxen
- lan lan
- pain
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims description 222
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title claims description 31
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title description 122
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title description 122
- 229960004380 tramadol Drugs 0.000 title description 95
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 66
- 150000003839 salts Chemical class 0.000 claims description 50
- 208000002193 Pain Diseases 0.000 claims description 49
- 229960002009 naproxen Drugs 0.000 claims description 32
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 30
- 230000036407 pain Effects 0.000 claims description 30
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 20
- 239000006185 dispersion Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims 3
- 241000935985 Certhiidae Species 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 239000000571 coke Substances 0.000 claims 1
- 238000004939 coking Methods 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- -1 salt salt Chemical class 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 235000013616 tea Nutrition 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- 239000000243 solution Substances 0.000 description 46
- 239000012453 solvate Substances 0.000 description 38
- 239000012458 free base Substances 0.000 description 33
- 229960000590 celecoxib Drugs 0.000 description 32
- 239000000203 mixture Substances 0.000 description 32
- CMWTZPSULFXXJA-SECBINFHSA-N (2R)-2-(6-methoxy-2-naphthalenyl)propanoic acid Chemical compound C1=C([C@@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-SECBINFHSA-N 0.000 description 28
- 239000002585 base Substances 0.000 description 28
- 239000002904 solvent Substances 0.000 description 22
- 239000003814 drug Substances 0.000 description 16
- 238000000634 powder X-ray diffraction Methods 0.000 description 16
- 239000008186 active pharmaceutical agent Substances 0.000 description 15
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 15
- 208000004454 Hyperalgesia Diseases 0.000 description 14
- 239000013543 active substance Substances 0.000 description 14
- 208000000094 Chronic Pain Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000002411 thermogravimetry Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 206010053552 allodynia Diseases 0.000 description 11
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 208000004296 neuralgia Diseases 0.000 description 9
- 208000021722 neuropathic pain Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000000113 differential scanning calorimetry Methods 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 208000001640 Fibromyalgia Diseases 0.000 description 7
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 6
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 6
- 208000035154 Hyperesthesia Diseases 0.000 description 6
- 208000005298 acute pain Diseases 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229940005483 opioid analgesics Drugs 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 206010034464 Periarthritis Diseases 0.000 description 5
- 239000004411 aluminium Substances 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 201000001119 neuropathy Diseases 0.000 description 5
- 230000007823 neuropathy Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 4
- 206010058019 Cancer Pain Diseases 0.000 description 4
- 208000008765 Sciatica Diseases 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 201000010603 frozen shoulder Diseases 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000011903 deuterated solvents Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000001144 powder X-ray diffraction data Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000009877 rendering Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 229960003107 tramadol hydrochloride Drugs 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- HJMPSKKJHVWPBK-UHFFFAOYSA-N N-nitrososarcosine Chemical compound O=NN(C)CC(O)=O HJMPSKKJHVWPBK-UHFFFAOYSA-N 0.000 description 2
- 101710164303 N-succinylamino acid racemase Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 101710125387 o-succinylbenzoate synthase Proteins 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000373 single-crystal X-ray diffraction data Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 208000008918 voyeurism Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241001080024 Telles Species 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005564 crystal structure determination Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000003612 morphinomimetic agent Substances 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 208000007771 sciatic neuropathy Diseases 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UBCKGWBNUIFUST-YHYXMXQVSA-N tetrachlorvinphos Chemical compound COP(=O)(OC)O\C(=C/Cl)C1=CC(Cl)=C(Cl)C=C1Cl UBCKGWBNUIFUST-YHYXMXQVSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (2)
- ïïï s «ÿ'^ N: !. Egy kokmîàlv. amely írapgéblí. azJrfvÄk fbmtófeaa vagy Iktóéglaiisg öllEgmtelá ^éMni valamin* naproxens sart-önssz, annok enantiorneid v«u> són ahol a s sammle: (S a msproxèn komát ? snél&râns 1:2. 2i Egy 1. igéo)pooî saentnj kokrûîtàly, ahol a naptoxlstt ágy tdnszijnk Kl hogy ha bssxeha.soolhjïik orooo^v ® 5î 0' vol d ' n s v» osa gui' » %n ν>Λ kv \\c\v ♦ !i»\*a*v«jteàl'it*tv“ my ngeumî: oas ns νΚΛ > h m i , w'k'í s sà s mm kö&Ä 1 y dùi?\s-Vàiasza nôveh.szik; ès1 vagy o a kokristály hatásossága növekszik; és/vagy o a kokmtály oklôslàs» növekszik; &»λ agy «· « kokrlstály bsolágiss huzzáterbeUisége aö^ oksglfcs; ásívagy * a h' 4r\t,;!;. Ό ,'Όο/ί Í TVOOhsilh, Cs V»gs * a kokristály iugroszképosságs csökken; és/vagy « *5 kokä'isTiälv sktkjantsk váltomssovsága csökken: és-' vasry * & kokrissáiy snodblb«» vitetik< 4. Λ/. í. vSgy 2. iyènyponï sxensïU kokmoby »! sa: NSAID (S.bmtproxén vagy (R}-napr0xén vsgy ezek só! 4 Älkk^ siinypÄok Mrmeiyskc saerf krftrfy; ahol rtmmatiol * · sáísírföí v«gy (eHngrfoI; i. £g> 1-4. igénypontok bármelyike v/vríoti kokdstálv arfábbiak köréből választva: * oi'y kiîsi.âh am h » t * x>^ \> s ih» * Ive s t< î, h n í ; niyc^a' ^ loá eo * > > \ ni val^ríat^^ftápo^éptitaftábBí^;' * u> kokv S\ t V iîïxK uokI ^ s>ü b u«»' r κ * ‘ m v kv> émö sóként vslanms (i?)-naproxens ludsdmaz; * ; ; î:T;i;ïadi4: szabad hszis lormálxm vagy isxsrlögüniag esSognohsöo sokem valamint t-Sy sap.owi't m tvähnsi/O lek mtaKok cs v '-xoinsvk h m οόΊ ! aim '>'<»» siao ' *; ' Ivm oganktg vhov ühí^v'' kent \ t ( k * »Hip bviaioí kosí»uai'',H'. “'\.ííki ot-eseko e hásOicfv Cc?(ts kokrssíály amely szóivá! kohrisuby, előnyösen s!konos-sa.o!sár K.otíj'ií>ii||y. legalOny ősibben nsetsnscdnsiik átkökríkklly. *>, 1 * svenypo', s otnri K"^'í»taK, O'U m'.nóo'; ' \4 no ö-rss n nsnktss v *gv ο^-ο^ρίηΐοο giltígadlmtó sóként ^îMîsiϊΐί ρísriíiéíít tsï^tsïlïîî =sss v^y p|*h'säm3döll^s:^bad :b;^is ibrmafemkM|p îî?i»'iogï,»î,4t» d'-gad'muo vók'sd wizard kkwgroxód :λγ- vow, '·-w.y tven koknsktiyok V 'S í \\ kWs' · J *Z Λ V k κΛ. . W ,Vi ν' ''Λν^Α(Α\^ sCOnn!hX<4 k* uvtoj ! ' í '
- 45, IÖ:5A:5%5,dkA 13¾¾¾ 0,2, là,?, }4,5, 14.0, kl ,8, 15,5, IS.?, 16,0, 16,2, Π,Ο, 17,4, 17,9, 18.1, ίδΛ ; 2. '{. '4-'·. 14" 50 I. 3υ,~. 30Jk 3kk 21.Α 31,9 η- 31,Κ Κ| ertehvknei »mua woowd, amdv 2 ihda érdkskes. sxk-spgàr {€»;<*< 14Ι060Λ) alkdii^^ávBl kspfelíj vagy a kokreíályok mednohszdvál alakba» v&rmak jelen. amely I fj-tramadoll szádul bázis formában vagy fiidölóglaílag eltagadható sóként valamin! <71 j-napj-oxém tartabnaz, azzal jdbmssve, itögy 3 por-K'sngenbiiïralci^ spduwntbxn : theta' -hk o,m (>\4 "\2 hdk M.O. Ι',λ kk\ 12,x 4,', l'.0, 1 3-2, 13.8, 14,9, 15,4. 16,2, Π,2, 17.6. 18,k 18,5. 19,1. 19,3. 19.6. 19.9, 20,1, 20,4, 20,0, 21.0. 21.S. 23,0, 22,3 óv 23.5 Tj dxekvknd mnon exu'Wkr, amok ? theta értékeket i3z-.vag,bzàà (Cím.,. ] ,54050.3.} alkalmazásával kaptak. ?· Bgy k s|iay^t^eÄtkkökrsat01y, amely (--MranKidolí szabad ház« ionná bars «agy fjglpldgktiäg: elfogadható sóként vlldtdnt (ly-nagioxdni tamlmgf \tggy ( ♦ Kramadolt xaubad bágis lonoSbsb yggy pAolOgidíag elfogadható sókém valamid (ííVoapmyénf tarldmmy vagy catvn koktisíálvok «iwrtiomcreindk kevMgkd, eml ,,jelhmtem. bogy m alábbi kiterjedésekkel mtdolteé. opneklin CgvOgWÜ s! s vo' a « 0,5 i 2< 2} \ b “ 40.5735(1 !) A c ::: 10.323(4} A 0 - Oik ft - 05.20(1 )"-γ4 90" vsgv \sko ns Mum, ,N,\»baO >,u v bas nkm w,r - ,ïoi.n m as· o^g-etme - ^oa; ·. sj.nn ' t < s> 4.'«o'ai0 .andni ww , 0 snmddt s, 4 k1 v, n Ι«μ,\> s >ws' is esnünk 3,' <vA vnkém valamint (An-smpm.xéd tartalma?, \.»gy ízen kokmtâlyok ea&mfome? keverékek asæal jelien teas'«, how sï mvaem-m-omsk medddp éles endoíerrn ísaac.-: kezdete 82-84 !'C. k, t'1-,η,Η eg'< 5 syenytví,' s,!«mmM'vr.otat\ ek-slln o,áio. an«d> a. kaH-s !sa shuaíaa (a) «apróin feloldása 0¾ Szns?pendaiasa egy dd&zerbesg .«« m- &ÍM, .vagy. diszperzió sneisgiíksa *.-gy' szobahőmérsókidnel ütiplÄ· <Μ:. »Ä.. ^ sguygpstÄ torrásponljimál alacsony abb hőmét^ékiatra; (B) tu lépéssel együtt* vsgv uts«a* f*i «ife s&hnâ· bàsis formébss vngy JkietógiaBaf vi?Vgad?ïOs> sátón seknkKk i * Vtw&nU'’ teloUksa egy okkwrhere adou eseOvn as (*> iqvssd ken>>naka cv uî> Vpe-dvn fek>"Y\o napïou^-ui nun egsunkno kanunk'' k ioUâeaxok (c) adott esetben a (b) oldat k>zx:áadáss i«: (s) bidatkas ès bsssskevçrèsôk : fd) miott esetkén agy oMkettt W^áása a* Í&X ?bl vagy *c) ohUboi és ôsssekos érésük; Ce.s az >„;»?, i k). u:i vagy (d) lépésben Iia;-sxk iddâksxuszpeeziè: lehűtése sxobahèrnérsékfetra vggy annál 2 kK ae-nvahh hőmérsékletre; (0 adott i>eUnm ex oldésser egy részének vagy égésiének elpátoiogíatása; ès (g.) a kapott koknstâlyok sxbrése. '» vHogya^m he*/noseov axnn Kdemexse hogy a/ k- igénypontok bármelyike ?'νπηΟ Vakust ily tetáptásso hatásos menny iségéé tartalmazna ^ H), As I sgényporitok bamtdyike sxerind kokmtáiy iáidalonn ctfa><Ken «kn? fájdalom. króniktts fäjdaiom. ocmopútlás iajslaUmu ethsnsi a képesig tetjsdd ftyMom» htptstäig&tN» »ltadfaia vi£r ráM's fajdalmre beleértve a diabetikus nemopnlist vagy diabetikus perifériás ttanwyMmM. tó· osAeoanrmszh ftbromtafgia; reurnàx tttimki BtA'hietaw-kô? (spondylitis aîtky)opoôtkak;M»'<m· váfí vagy isiász kezeléseken való alkalmazásra.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20080384012 EP2177215A1 (en) | 2008-10-17 | 2008-10-17 | Co-crystals of tramadol and NSAIDs |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE030976T2 true HUE030976T2 (hu) | 2017-06-28 |
Family
ID=40673614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE09736862A HUE030976T2 (hu) | 2008-10-17 | 2009-10-16 | Tramadol és NSAID-ok kokristályai |
Country Status (27)
Country | Link |
---|---|
US (10) | US20110257134A1 (hu) |
EP (2) | EP2177215A1 (hu) |
JP (1) | JP5645830B2 (hu) |
KR (1) | KR101679400B1 (hu) |
CN (1) | CN102186465B (hu) |
AU (1) | AU2009304235B2 (hu) |
BR (1) | BRPI0920358A2 (hu) |
CA (1) | CA2737754C (hu) |
CY (1) | CY1118374T1 (hu) |
DK (1) | DK2349238T3 (hu) |
ES (1) | ES2603962T3 (hu) |
HR (1) | HRP20161526T1 (hu) |
HU (1) | HUE030976T2 (hu) |
IL (1) | IL211785A (hu) |
IN (1) | IN2012DN01435A (hu) |
LT (1) | LT2349238T (hu) |
MX (1) | MX336318B (hu) |
MY (1) | MY156285A (hu) |
NZ (1) | NZ591873A (hu) |
PL (1) | PL2349238T3 (hu) |
PT (1) | PT2349238T (hu) |
RU (1) | RU2599717C2 (hu) |
SI (1) | SI2349238T1 (hu) |
SM (1) | SMT201600439B (hu) |
UA (1) | UA109534C2 (hu) |
WO (1) | WO2010043412A1 (hu) |
ZA (1) | ZA201102762B (hu) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2177215A1 (en) * | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
SI2488169T1 (sl) * | 2009-10-16 | 2013-05-31 | Laboratorios Del Dr. Esteve, S.A. | Ko - kristali iz tramadola in koksibov |
EP2392319A1 (en) * | 2010-06-04 | 2011-12-07 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compositions of co-crystals of tramadol and coxibs |
JP2013535438A (ja) * | 2010-07-12 | 2013-09-12 | ユン シン ファーマシューティカル インダストリアル カンパニー,リミティド | トラマドールのジクロフェナク塩 |
DE102010063609A1 (de) * | 2010-12-20 | 2012-06-21 | Awd.Pharma Gmbh & Co. Kg | Neue Multikomponentenkristalle aus ([2-Amino-6-(4-fluoro-benzylamino)-pyridin-3yl)-carbamidsäureethylester und einer Arylpropionsäure |
KR101888852B1 (ko) | 2011-12-02 | 2018-09-21 | 삼성전자주식회사 | 휴대용 단말기에서 다이버시티 서비스를 제공하기 위한 장치 및 방법 |
GB201222287D0 (en) | 2012-12-11 | 2013-01-23 | Ct For Process Innovation Ltd | Methods for making active crystalline materials |
ITMI20130210A1 (it) * | 2013-02-14 | 2014-08-15 | Menarini Lab | Composizioni farmaceutiche contenenti dexketoprofene e tramadolo |
RU2542100C1 (ru) * | 2013-12-24 | 2015-02-20 | Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской Академии Наук (ИХС РАН) | Сокристаллическая форма теофиллина с дифлунисалом или диклофенаком |
WO2016116942A1 (en) | 2015-01-20 | 2016-07-28 | Anlon Chemical Research Organization | Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin |
CN104592009B (zh) * | 2015-02-09 | 2017-02-22 | 黑龙江大学 | 萘普生药物共晶及其制备方法 |
US9693949B1 (en) * | 2015-12-22 | 2017-07-04 | Revogenex Ireland Ltd | Intravenous administration of tramadol |
MX2016006464A (es) * | 2016-05-18 | 2017-11-17 | Laboratorios Liomont S A De C V | Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor. |
BR112019018418A2 (pt) * | 2017-03-08 | 2020-04-14 | Intercept Pharmaceuticals Inc | formas cristalinas do ácido obeticólico |
WO2019122982A1 (en) | 2017-12-21 | 2019-06-27 | Grünenthal GmbH | Pharmaceutical combination in a bilayer tablet form comprising ketorolac tromethamine and tramadol hydrochloride, and its use in pain treatment |
WO2019130049A1 (en) | 2017-12-29 | 2019-07-04 | Grünenthal GmbH | Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain |
US11510926B2 (en) | 2018-05-31 | 2022-11-29 | The Royal Institution For The Advancement Of Learning/Mcgill University | Pharmaceutical salts/co-crystals of pentoxifylline, clonidine and linsidomine with caffeic, protocatechuic or alpha-lipoic acid an use thereof for treatment of pain |
CA3110155A1 (en) * | 2018-08-20 | 2020-02-27 | Mylan Laboratories Limited | Tramadol hbr-celecoxib co-crystal |
WO2020121326A1 (en) | 2018-12-13 | 2020-06-18 | Mylan Laboratories Limited | Amorphous (rac)-tramadol.hcl-celecoxib (1:1) |
JP2022533580A (ja) * | 2019-05-14 | 2022-07-25 | エステベ ファーマシューティカルズ,ソシエダッド アノニマ | トラマドールの濫用傾向を低減させながら疼痛を治療するためのトラマドールおよびセレコキシブからなる共結晶の使用 |
EP4169903A1 (en) * | 2021-10-25 | 2023-04-26 | Dompe' Farmaceutici S.P.A. | Co-crystals of nonsteroidal anti-inflammatory drugs, lysine and gabapentin, pharmaceutical compositions and their medical use |
KR20240027436A (ko) * | 2022-08-23 | 2024-03-04 | 대원제약주식회사 | 펠루비프로펜 및 트라마돌의 이온결합 화합물, 이를 포함하는 조성물, 및 이의 제조 방법 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3652589A (en) | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
KR100243956B1 (ko) | 1991-09-06 | 2000-03-02 | 랄프 알. 팔로 | 트라마돌 물질 및 아세트아미노펜을 포함하는 통증 치료용 약제학적 조성물 |
AU661723B2 (en) * | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
US5516803A (en) | 1991-10-30 | 1996-05-14 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
DK0924201T3 (da) | 1993-11-30 | 2002-05-21 | Searle & Co | Tricyclisk substitueret pyrazolylbenzensulfonamider og deres anvendelse som cyclooxygenase II-inhibitorer |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
PL195955B1 (pl) | 1996-04-12 | 2007-11-30 | Searle & Co | Związek, pochodna benzenosulfonamidu, sposób jegowytwarzania, kompozycja farmaceutyczna zawierająca go oraz jego zastosowanie |
US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
HU227732B1 (en) | 1996-07-18 | 2012-01-30 | Merck Frosst Canada Ltd | Substituted pyridine derivatives as selective cyclooxigenase-2 inhibitors and use thereof |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
RS49982B (sr) | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
NZ513924A (en) * | 1999-03-01 | 2001-09-28 | Ortho Mcneil Pharm Inc | Composition comprising a tramadol material and a selective cox-2 inhibitor drug |
DE19927688A1 (de) | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
DE10108122A1 (de) | 2001-02-21 | 2002-10-02 | Gruenenthal Gmbh | Arzneimittel auf Basis von Tramadol |
ES2351249T3 (es) | 2001-07-27 | 2011-02-02 | Astellas Pharma Inc. | Composición que comprende partículas finas, de liberación sostenida, para comprimidos de disgregación rápida en la cavidad bucal. |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
OA12778A (en) | 2002-02-19 | 2006-07-06 | Adcock Ingram Ltd | Pharmaceutical combination of COX-2 inhibitors andipiates. |
ATE370264T1 (de) | 2002-07-17 | 2007-09-15 | Soitec Silicon On Insulator | Verfahren zur herstellung von substraten, insbesondere für die optik, elektronik und optoelektronik |
CN1245968C (zh) | 2002-10-09 | 2006-03-22 | 新疆特丰药业股份有限公司 | 一种萘普生钠缓释片剂的制备方法 |
CA2513064C (en) | 2003-01-31 | 2009-11-10 | Elan Pharma International, Ltd. | Nanoparticulate topiramate formulations |
EP1631260A2 (en) * | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
JP2007516259A (ja) | 2003-12-09 | 2007-06-21 | メッドクリスタルフォームズ、エルエルシー | 活性剤との混合相共結晶の調製方法 |
US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
DE102006056458A1 (de) * | 2006-11-28 | 2008-05-29 | Grünenthal GmbH | Arzneimittelzubereitung von Tramadol und Acetaminophen |
WO2008085674A1 (en) | 2007-01-04 | 2008-07-17 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions comprising celecoxib co-crystals |
US20080031950A1 (en) * | 2007-04-27 | 2008-02-07 | Nectid Inc. | Novel anelgesic combination |
EP2022778A1 (en) * | 2007-08-07 | 2009-02-11 | Laboratorios del Dr. Esteve S.A. | A crystalline form of (R,R)-tramadol-(S)-naproxene salt |
BRPI0912326A2 (pt) | 2008-05-20 | 2015-10-06 | Neurogesx Inc | análogos de acetaminofeno hidrossolúveis |
SI2326632T1 (sl) | 2008-09-06 | 2017-11-30 | Bionevia Pharmaceuticals, Inc. | Nov kokristal holin epalrestata |
EP2177215A1 (en) * | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
CA2771665C (en) | 2009-10-16 | 2015-10-06 | Laboratorios Del Dr. Esteve, S.A. | Co-crystals of tramadol and coxibs |
EP2311446A1 (en) | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
SI2488169T1 (sl) * | 2009-10-16 | 2013-05-31 | Laboratorios Del Dr. Esteve, S.A. | Ko - kristali iz tramadola in koksibov |
CA2797829A1 (en) * | 2010-05-07 | 2011-11-10 | Carefusion 2200, Inc. | Method of producing pleurodesis |
EP2392319A1 (en) * | 2010-06-04 | 2011-12-07 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compositions of co-crystals of tramadol and coxibs |
JP2022533580A (ja) * | 2019-05-14 | 2022-07-25 | エステベ ファーマシューティカルズ,ソシエダッド アノニマ | トラマドールの濫用傾向を低減させながら疼痛を治療するためのトラマドールおよびセレコキシブからなる共結晶の使用 |
-
2008
- 2008-10-17 EP EP20080384012 patent/EP2177215A1/en not_active Withdrawn
-
2009
- 2009-10-16 RU RU2011119608/04A patent/RU2599717C2/ru active
- 2009-10-16 KR KR1020117010637A patent/KR101679400B1/ko active IP Right Grant
- 2009-10-16 MX MX2011003612A patent/MX336318B/es unknown
- 2009-10-16 US US13/124,027 patent/US20110257134A1/en not_active Abandoned
- 2009-10-16 AU AU2009304235A patent/AU2009304235B2/en not_active Ceased
- 2009-10-16 PL PL09736862T patent/PL2349238T3/pl unknown
- 2009-10-16 CN CN200980141056.6A patent/CN102186465B/zh not_active Expired - Fee Related
- 2009-10-16 NZ NZ591873A patent/NZ591873A/xx not_active IP Right Cessation
- 2009-10-16 SI SI200931565A patent/SI2349238T1/sl unknown
- 2009-10-16 HU HUE09736862A patent/HUE030976T2/hu unknown
- 2009-10-16 DK DK09736862.5T patent/DK2349238T3/en active
- 2009-10-16 JP JP2011531401A patent/JP5645830B2/ja not_active Expired - Fee Related
- 2009-10-16 WO PCT/EP2009/007451 patent/WO2010043412A1/en active Application Filing
- 2009-10-16 LT LTEP09736862.5T patent/LT2349238T/lt unknown
- 2009-10-16 BR BRPI0920358-3A patent/BRPI0920358A2/pt not_active Application Discontinuation
- 2009-10-16 PT PT97368625T patent/PT2349238T/pt unknown
- 2009-10-16 CA CA2737754A patent/CA2737754C/en not_active Expired - Fee Related
- 2009-10-16 EP EP09736862.5A patent/EP2349238B1/en active Active
- 2009-10-16 ES ES09736862.5T patent/ES2603962T3/es active Active
-
2010
- 2010-04-19 MY MYPI2012000675A patent/MY156285A/en unknown
- 2010-04-19 UA UAA201205792A patent/UA109534C2/uk unknown
- 2010-04-19 US US13/395,021 patent/US8598152B2/en active Active
- 2010-04-19 IN IN1435DEN2012 patent/IN2012DN01435A/en unknown
-
2011
- 2011-03-17 IL IL211785A patent/IL211785A/en active IP Right Grant
- 2011-04-13 ZA ZA2011/02762A patent/ZA201102762B/en unknown
-
2013
- 2013-10-29 US US14/066,127 patent/US9012440B2/en active Active
-
2014
- 2014-07-07 US US14/324,448 patent/US9393220B2/en active Active
-
2015
- 2015-03-23 US US14/665,055 patent/US20150196503A1/en not_active Abandoned
- 2015-03-23 US US14/665,060 patent/US20150196504A1/en not_active Abandoned
-
2016
- 2016-07-12 US US15/207,694 patent/US10238668B2/en active Active
- 2016-08-09 US US15/231,915 patent/US10245276B2/en active Active
- 2016-11-18 HR HRP20161526TT patent/HRP20161526T1/hr unknown
- 2016-11-22 CY CY20161101201T patent/CY1118374T1/el unknown
- 2016-11-30 SM SM201600439T patent/SMT201600439B/it unknown
-
2019
- 2019-02-14 US US16/275,437 patent/US10548909B2/en active Active
- 2019-12-19 US US16/720,574 patent/US11478488B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE030976T2 (hu) | Tramadol és NSAID-ok kokristályai | |
JP2011520933A (ja) | 疼痛の治療用の、デュロキセチンとコックス阻害剤との共結晶 | |
US20230057884A1 (en) | Co-crystals of tramadol and coxibs | |
US8168679B2 (en) | Salts of Tramadol and Naproxen and their crystal forms in the treatment of pain | |
RU2547830C2 (ru) | Сокристаллы трамадола и коксибов | |
EP2199274A1 (en) | Co-crystals of tramadol and paracetamol | |
WO2009109401A1 (en) | Salts of memantine and cox-inhibitors and their crystalform in the treatment of pain |